A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis

Trial Profile

A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
  • Indications Urinary tract infections
  • Focus Adverse reactions
  • Acronyms MK-7625A-034
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Oct 2017 Planned initiation date changed from 22 Dec 2017 to 18 Jan 2018.
    • 07 Sep 2017 Planned initiation date changed from 13 Oct 2017 to 22 Dec 2017.
    • 17 Aug 2017 Planned initiation date changed from 1 Sep 2017 to 13 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top